NICE has been recommended for reimbursement of Epidyolex (cannabidiol, 100mg/mL oral solution) as adjunctive therapy for patients aged ≥2yrs. with seizures associated with tuberous sclerosis complex (TSC)
This recommendation ensures that starting on Mar 2023, all eligible UK patients who might benefit from this medication will be able to receive reimbursed access to Epidyolex
The therapy has been approved for use in the UK under three conditions & also been approved in the EU. The therapy also received marketing authorization under the trade name Epidyolex as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome or Dravet syndrome in conjunction with clobazam
Ref: Jazz Pharma | Image: Jazz Pharma
Related News:- Jazz Reports the Initiation of Epidiolex/Epidyolex (cannabidiol) in P-III (GWEP20238) Trial for Epilepsy Associated with Myoclonic-Atonic Seizures
